Loading page...
Continued supply of Zephex® 134a
Continuous support for our industry with secured Zephex® 134a supply
Supporting patients and partners worldwide.
Zephex® 134a has been the world’s most trusted medical propellant for metered dose inhalers (MDIs) for more than 30 years. Around the globe, millions of patients depend on Zephex® 134a every day for safe, effective delivery of life-saving respiratory medicines used to treat asthma and COPD.
At Orbia Fluor & Energy Materials we are committed to ensuring the reliable, long-term supply of Zephex® 134a — both in today’s world and also into the future — as the healthcare industry continues to evolve.
A commitment built on reliability and investment
Continuity of supply is central to patient wellbeing. To safeguard this, we are investing significantly in our Orbia Fluor & Energy Materials site in Runcorn, UK, the world’s largest integrated facility for pharmaceutical-grade HFC production. This investment strengthens our ability to:
Guarantee ongoing production capacity for Zephex® 134a in support of global market demand.
Enhance manufacturing resilience through upgraded, energy-efficient infrastructure.
Support future innovation, including delivery-at-scale of the next-generation, low-GWP medical propellant Zephex® 152a.
By continuing to invest in our Runcorn site, we are ensuring that our customers can continue to access Zephex® 134a with confidence, in line with market demand — supported by a supply chain designed for consistency, compliance, and quality.
Reliable supply — Global reach, local commitment
Our globally integrated supply network, enables delivery of Zephex® 134a to pharmaceutical partners across Europe, North America, Asia, and beyond.
Our operations are designed to provide:
Security of supply, with capacity planning aligned to market needs. A strengthened supply chain with three independent feed stock sources split across three geographical regions.
Quality assurance, through rigorous product testing and traceability at every stage. Continued updates and alignment for DMF, market access, regulatory & compliance activities.
Regulatory and technical support for customers, ensuring seamless integration into existing MDI formulations.
Customer-focused logistics, tailored to regional requirements and delivery schedules.
F-Gas consumption within the EU and reporting for regulatory compliance.
Sustaining today, innovating for tomorrow
While Zephex® 134a continues to play a vital role in current inhaler formulations, we are also driving the low-GWP propellant transition with our Zephex® 152a solution which reduces the carbon emissions by 90% compared to the existing propellant, supporting our customers with their own smooth transitions and drive to fulfil their sustainability goals. Our goal is to ensure that no patient’s access to treatment is disrupted, whether through today’s trusted propellants or tomorrow’s sustainable, lower-GWP alternatives.
Why partner with Orbia Fluor & Energy Materials?
Our Strength
- Runcorn, UK site receives continued investment
- Global network
- High-purity, pharmaceutical-grade Zephex® 134a
- Customer-focused support
- Global network
- Commitment to innovation
Your Benefit
- Long-term production capacity and resilience
- Consistent, reliable supply worldwide
- Proven safety and performance in MDIs for over 30 years
- Technical, regulatory, and logistics expertise
- A partner for both today and the future
Speak with one of our experts
Do you have a question regarding medical propellants for one of our experts?
Document downloads
Here you can download additional support materials for our medical propellants and other informative resources such as flyers, white papers and guides.
Related articles
view all related articles.png&w=3840&q=75)
Announcement
Pharma
Zephex
+1
Media Center
The transition in action: When innovation meets collaboration, even the sky isn’t the limit
21 January 2026
Press Release
OF&EM
Pharma
+3
Media Center
Orbia Fluor & Energy Materials delivers first ISO tank of low-GWP propellant
14 October 2025
Press Release
Announcement
OF&EM
+3
Media Center
Orbia Fluor & Energy Materials unveils new team to lead pharmaceutical division
19 March 2025